



Rx WIRE

A weekly service from
Pharmaceutical Strategies Group.

January 13, 2017

Creating opportunity for our clients with an exclusive focus on pharmacy solutions.

Republican-led Senate takes first step to repeal 'Obamacare'

Associated Press - January 12



The Senate early Thursday passed a measure to take the first step forward on dismantling President Barack Obama's health care law, responding to pressure to move quickly even as Republicans and President-elect Trump grapple with what to replace it with.

[READ MORE](#)

SUMMARY OF TOP ARTICLES

Specialty Pharmacies Say Benefit Managers Are Squeezing Them Out

NYTimes - January 9

From its storefront in Union City, N.J., Prime Aid Pharmacy caters to patients with a wide range of ailments, from rheumatoid arthritis to hepatitis C.

Egalet painkiller wins FDA approval but label disappoints

Reuters - January 9

The U.S. Food and Drug Administration on Monday approved Egalet Corp's long-acting opioid painkiller, Arymo ER, and will allow the company to claim it deters abuse by those seeking to dissolve and inject it.

Few black diabetes patients in US drug trials

Fox News - January 9

Even though diabetes rates are almost twice as high in black people as in

PBMI
WEBINAR



Findings from
PBMI's 2016
Pharmacy Trends

whites, black patients may be far less likely to be included in drug safety trials, a recent study suggests.

Report: Pharmacists dispensing dangerous drug combos

DrugTopics - January 9

Walgreens, CVS Health and other drug chains promised to improve procedures after a *Chicago Tribune* investigation found that pharmacists at several retail chains filled prescriptions with dangerous drug combinations.

Studies find worrying over- and underuse of medicine worldwide

Reuters - January 8

Up to 70 percent of hysterectomies in the United States, a quarter of knee replacements in Spain and more than half the antibiotics prescribed in China are inappropriate, overused healthcare, researchers said on Monday.

New 340B drug rule sets drugmaker fines

Formulary Journal - January 9

Consumer health groups are praising Health and Human Services' (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.

Mylan's EpiPen Sales Plan: Schools Today, Everywhere Tomorrow

Bloomberg - January 6

Mylan NV got EpiPen allergy shots stocked in schools across America with free programs and special discounts.

CVS slashes price of Impax's EpiPen rival

Reuters - January 12

Drugstore chain CVS Health Corp (CVS.N) has cut the price of a generic version of Impax Laboratories Inc's (IPXL.O) emergency allergy injection, a device similar to Mylan NV's (MYL.O) controversial EpiPen.

Medication Adherence a Problem With in AFib Patients

Drug Discovery & Development - January 10

For patients with atrial fibrillation, the most common form of heart arrhythmia, a main goal of treatment is stroke prevention.

Medicare to Cover Infliximab Biosimilar

MedPage Today - January 6

Pfizer announced Friday that Medicare has released reimbursement information for the biosimilar Inflectra (infliximab-dyyb).

Common morning sickness drug may not work

Reuters - January 4

A pill routinely prescribed for morning sickness may not be an effective nausea remedy, researchers say - although not all doctors agree.

Heartburn Drugs May Raise Risk of Stomach Infections: Study

HealthDay News - January 5

People who take heartburn drugs such as Prilosec and Nexium may be at increased risk of two potentially serious gut infections, a new study suggests.

in ACOs Report

January 24, 2017

1:30pm Eastern

FREE!

CLICK HERE TO

RESERVE YOUR
SEAT TODAY!



Pharmacy Benefit
Management Institute

FDA NEWS

FDA Approves New Indication for Eye Drug Lucentis

Managed Care - January 6

The FDA has approved ranibizumab (Lucentis, Genentech) 0.5-mg injection for the treatment of patients with myopic choroidal neovascularization (mCNV), a complication of severe near-sightedness that can lead to blindness.

New FDA Drug Approvals: Breaking Down the Numbers

Regulatory Affairs Professionals Society - January 4

If a decline in US Food and Drug Administration (FDA) approvals of new pharmaceuticals is a bad sign for the industry, then 2016 was the worst year since 2010.



Copyright © 2017 Pharmaceutical Strategies Group LLC. All rights reserved.

www.psgconsults.com | 800.687.4404

2901 N. Dallas Pkwy. Suite #420 | Plano, TX 75093

ABOUT YOUR SUBSCRIPTION

You have received this email because you are signed up to receive RxWire from Pharmaceutical Strategies Group LLC. If you would like to stop receiving the RxWire newsletter, please [manage your preferences](#). If you know someone who would be excited to hear from us as well, [forward this email to your friend](#). If your email address has changed, please [update your account](#). Your privacy is our responsibility, and know that we do not rent, share or sell your email address or contact information with anyone. This email was sent to ckosha@nnebt.org.